Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX2004 in Advanced or Metastatic Solid Tumors
NCT07085091Phase 1Recruiting
- Sponsor
- ALX Oncology
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of ALX2004 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 1 more (3 arms), sponsored by ALX Oncology. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment Emergent Adverse Events at 2 years and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
ALX2004
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07085091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085091.